Medicine and Dentistry
Cost-Effectiveness Analysis
100%
Health Care Cost
68%
Quality Adjusted Life Year
54%
Population Health
54%
Surgical Technique
41%
COVID-19
39%
Quality of Life
36%
Disability Adjusted Life Years
30%
Surgery
21%
Clinical Trial
18%
Onasemnogene Abeparvovec
18%
Nusinersen
18%
Spinal Muscular Atrophy
18%
Pituitary Adenoma
18%
Diffuse Large B-Cell Lymphoma
18%
Chimeric Antigen Receptor T-Cell Immunotherapy
18%
Octreotide
18%
Remdesivir
18%
Lisocabtagene Maraleucel
18%
Coronary Artery Disease
18%
Medical Device
18%
Growth Hormone Secreting Adenoma
18%
Lifespan
16%
Axicabtagene Ciloleucel
15%
Magnetic Resonance Imaging
14%
Randomized Controlled Trial
13%
Autologous Stem Cell Transplantation
12%
Heart Death
10%
Base
10%
Health Care
9%
Chemoimmunotherapy
9%
Lopinavir/Ritonavir
9%
Tocilizumab
9%
Dexamethasone
9%
Baricitinib
9%
Health Status
9%
Hydroxychloroquine
9%
Beta1a Interferon
9%
Diseases
9%
Coronary Computed Tomography Angiography
7%
Overall Survival
6%
Supportive Care
6%
Preoperative Treatment
5%
Nursing and Health Professions
Cost Effectiveness Analysis
45%
Quality Adjusted Life Year
28%
Chimeric Antigen Receptor T-Cell Immunotherapy
18%
Lisocabtagene Maraleucel
18%
Quality of Life
18%
Remdesivir
18%
Coronary Artery Disease
18%
Medical Device
18%
Diffuse Large B Cell Lymphoma
18%
Axicabtagene Ciloleucel
15%
Autologous Stem Cell Transplantation
12%
Heart Death
10%
Baricitinib
9%
Beta1a Interferon
9%
Incremental Cost-Effectiveness Ratio
9%
Lopinavir Plus Ritonavir
9%
Hydroxychloroquine
9%
Dexamethasone
9%
Tocilizumab
9%
Computer Assisted Tomography
7%
Coronary Angiography
7%
Remission
6%
Overall Survival
6%
Health Status
5%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
36%
Hypophysis Adenoma
18%
Coronary Artery Disease
18%
Remdesivir
18%
Onasemnogene Abeparvovec
18%
Spinal Muscular Atrophy
18%
Nusinersen
18%
Diseases
18%
Randomized Controlled Trial
13%
Heart Death
13%
Health Status
10%
Base
9%
Lopinavir Plus Ritonavir
9%
Dexamethasone
9%
Tocilizumab
9%
Baricitinib
9%
Hydroxychloroquine
9%
Beta1a Interferon
9%
Nonfunctioning Pituitary Adenoma
6%
Hexachlorophene
6%